Ovid Therapeutics Inc. (OVID)
Automate Your Wheel Strategy on OVID
With Tiblio's Option Bot, you can configure your own wheel strategy including OVID - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol OVID
- Rev/Share 5.3208
- Book/Share 44.6312
- PB 0.037
- Debt/Equity 0.0248
- CurrentRatio 4.7164
- ROIC -0.5948
- MktCap 117330698.0
- FreeCF/Share -32.0488
- PFCF -2.9288
- PE -0.054
- Debt/Assets 0.0179
- DivYield 0
- ROE -0.5883
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 5
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | OVID | Oppenheimer | -- | Outperform | -- | $7 | Oct. 9, 2025 |
| Resumed | OVID | B. Riley Securities | -- | Buy | -- | $3 | Aug. 8, 2025 |
News
OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data
Published: October 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Ovid Therapeutics jumps 39% in a month after phase I epilepsy study data show superior efficacy of its lead candidate, OV329, hinting at best-in-class potential.
Read More
Ovid Therapeutics (OVID) Is Up 42.98% in One Week: What You Should Know
Published: October 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Does Ovid Therapeutics (OVID) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
Ovid Therapeutics Inc. - Special Call
Published: October 03, 2025 by: Seeking Alpha
Sentiment: Neutral
Ovid Therapeutics Inc. - Special Call Company Participants Victoria Fort - Senior Vice President of Corporate Affairs & Corporate Strategy Jeremy Levin - CEO & Chairman Meg Alexander - President & COO Conference Call Participants Laura Chico - Wedbush Securities Inc., Research Division Ritu Baral - TD Cowen, Research Division Madison Wynne El-Saadi - B. Riley Securities, Inc., Research Division Myles Minter - William Blair & Company L.L.C.
Read More
Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds
Published: October 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
Initial closing of approximately $81 million expected to fund current operating plan and clinical pipeline into 2028, with potential for up to $94 million in additional proceeds upon exercise of issued warrants Initial closing of approximately $81 million expected to fund current operating plan and clinical pipeline into 2028, with potential for up to $94 million in additional proceeds upon exercise of issued warrants
Read More
Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile
Published: October 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today announced positive topline results from its Phase 1 healthy volunteer study evaluating the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) activity of OV329, a next generation GABA-aminotransferase (GABA-AT) inhibitor being developed for drug-resistant epilepsies.
Read More
Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates
Published: August 13, 2025 by: Zacks Investment Research
Sentiment: Neutral
Ovid Therapeutics (OVID) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to earnings of $0.12 per share a year ago.
Read More
Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Neutral
Ovid Therapeutics (OVID) came out with a quarterly loss of $0.14 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.17 per share a year ago.
Read More
Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Negative
Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that Meg Alexander, President and Chief Operating Officer, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 3:10 p.m. ET in Boston, Massachusetts.
Read More
About Ovid Therapeutics Inc. (OVID)
- IPO Date 2017-05-05
- Website https://www.ovidrx.com
- Industry Biotechnology
- CEO Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir,
- Employees 23